MedTrace Logo

Study of Denosumab in Subjects With Giant Cell Tumor of Bone

NCT00680992 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 535

Last updated 2022-09-22

Study results available
· View outcomes & findings →

Summary

To determine how safe denosumab is in treating subjects with giant cell tumor of bone (GCTB)

Conditions

  • Cancer
  • Giant Cell Tumors
  • Giant Cell Tumor of Bone
  • Benign Giant Cell Tumors

Interventions

DRUG

Denosumab

120 mg administered subcutaneously (SC) every 4 weeks (Q4W) with a loading dose of 120 mg SC on study days 8 and 15.

Sponsors & Collaborators

Principal Investigators

  • MD · Amgen

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-09-09
Primary Completion
2018-05-17
Completion
2018-05-17

Countries

  • United States
  • Australia
  • Austria
  • Canada
  • France
  • Germany
  • Italy
  • Netherlands
  • Poland
  • Spain
  • Sweden
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00680992 on ClinicalTrials.gov